Pluristem Therapeutics (NASDAQ:PSTI) Trading 7.8% Higher

Pluristem Therapeutics Inc. (NASDAQ:PSTI) traded up 7.8% on Monday . The stock traded as high as $3.68 and last traded at $3.61, 107,414 shares were traded during mid-day trading. An increase of 86% from the average session volume of 57,792 shares. The stock had previously closed at $3.35.

Several equities research analysts have weighed in on the company. Maxim Group reissued a “buy” rating and issued a $8.00 price target on shares of Pluristem Therapeutics in a report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $15.50 price target on shares of Pluristem Therapeutics in a report on Wednesday, November 13th. Finally, Zacks Investment Research upgraded Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $9.25.

The company has a quick ratio of 2.74, a current ratio of 2.74 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average price of $3.42 and a 200-day moving average price of $2.70.

Several large investors have recently made changes to their positions in the company. ARK Investment Management LLC raised its stake in shares of Pluristem Therapeutics by 35.9% in the second quarter. ARK Investment Management LLC now owns 5,156,645 shares of the biotechnology company’s stock worth $32,007,000 after purchasing an additional 1,363,396 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Pluristem Therapeutics by 107.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after purchasing an additional 974,306 shares during the last quarter. Nikko Asset Management Americas Inc. raised its stake in shares of Pluristem Therapeutics by 102.8% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after purchasing an additional 954,161 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Pluristem Therapeutics in the second quarter worth about $231,000. Finally, Jane Street Group LLC raised its stake in shares of Pluristem Therapeutics by 28.1% in the second quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 33,630 shares during the last quarter. Hedge funds and other institutional investors own 9.56% of the company’s stock.

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.